{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "cannabidiol (CBD)", "cytokine storm", "oral drug therapy", "solid lipid nanoparticles (SLN)", "tocilizumab (TCZ)"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37033914", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "11"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "03", "Day": "22"}], "Language": ["eng"], "ELocationID": ["1147991", "10.3389/fimmu.2023.1147991"], "Journal": {"ISSN": "1664-3224", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2023"}}, "Title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol"}, "ArticleTitle": "Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.", "Pagination": {"StartPage": "1147991", "MedlinePgn": "1147991"}, "Abstract": {"AbstractText": ["Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections."], "CopyrightInformation": "Copyright \u00a9 2023 Zieli\u0144ska, Eder, Karczewski, Szalata, Hryhorowicz, Wielgus, Szalata, Dobrowolska, Atanasov, S\u0142omski and Souto."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Human Genetics, Polish Academy of Sciences Poznan, Poznan, Poland."}], "LastName": "Zieli\u0144ska", "ForeName": "Aleksandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland."}], "LastName": "Eder", "ForeName": "Piotr", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Environmental Medicine/Department of Gastroenterology, Human Nutrition and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland."}], "LastName": "Karczewski", "ForeName": "Jacek", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Biotechnology, Pozna\u0144 University of Life Sciences, Pozna\u0144, Poland."}], "LastName": "Szalata", "ForeName": "Marlena", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Human Genetics, Polish Academy of Sciences Poznan, Poznan, Poland."}], "LastName": "Hryhorowicz", "ForeName": "Szymon", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland."}], "LastName": "Wielgus", "ForeName": "Karolina", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants National Research Institute, Poznan, Poland."}], "LastName": "Szalata", "ForeName": "Milena", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland."}], "LastName": "Dobrowolska", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Genetics and Animal Biotechnology, Magdalenka, Poland."}, {"Identifier": [], "Affiliation": "Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy, University of Vienna, Vienna, Austria."}], "LastName": "Atanasov", "ForeName": "Atanas G", "Initials": "AG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Human Genetics, Polish Academy of Sciences Poznan, Poznan, Poland."}], "LastName": "S\u0142omski", "ForeName": "Ryszard", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "UCIBIO - Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal."}, {"Identifier": [], "Affiliation": "Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal."}], "LastName": "Souto", "ForeName": "Eliana B", "Initials": "EB"}], "PublicationTypeList": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Immunol", "NlmUniqueID": "101560960", "ISSNLinking": "1664-3224"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Lipid Nanoparticles"}, {"RegistryNumber": "I031V2H011", "NameOfSubstance": "tocilizumab"}, {"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunosuppressive Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cannabidiol"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "Immunosuppressive Agents"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (Covid-19) outbreak. J Autoimmun (2020) 109:102433. doi: 10.1016/j.jaut.2020.102433", "ArticleIdList": ["10.1016/j.jaut.2020.102433", "PMC7127067", "32113704"]}, {"Citation": "Agrawal M, Saraf S, Saraf S, Murty US, Kurundkar SB, Roy D, et al. . In-line treatments and clinical initiatives to fight against covid-19 outbreak. Respir Med (2020) 106192.", "ArticleIdList": ["PMC7567661", "33199136"]}, {"Citation": "Malin JJ, Su\u00e1rez I, Priesner V, F\u00e4tkenheuer G, Rybniker J. Remdesivir against covid-19 and other viral diseases. Clin Microbiol Rev (2020) 34(1):e00162\u201320. doi: 10.1128/CMR.00162-20", "ArticleIdList": ["10.1128/CMR.00162-20", "PMC7566896", "33055231"]}, {"Citation": "Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. . Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of covid-19. ACS Cent Sci (2020). doi: 10.20944/preprints202004.0299.v1", "ArticleIdList": ["10.20944/preprints202004.0299.v1", "PMC7202249", "32483554"]}, {"Citation": "Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. . Remdesivir for the treatment of covid-19. New Engl J Med (2020). doi: 10.1056/NEJMoa2007764", "ArticleIdList": ["10.1056/NEJMoa2007764", "32649078"]}, {"Citation": "Spinner CD, Gottlieb RL, Criner GJ, L\u00f3pez JRA, Cattelan AM, Viladomiu AS, et al. . Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate covid-19: A randomized clinical trial. Jama (2020) 324(11):1048\u201357. doi: 10.1001/jama.2020.16349", "ArticleIdList": ["10.1001/jama.2020.16349", "PMC7442954", "32821939"]}, {"Citation": "Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe covid-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet (2020).", "ArticleIdList": ["PMC7190303", "32423584"]}, {"Citation": "Organization WH. Solidarity\u201d clinical trial for covid-19 treatments, in: World health organization (WHO) situation reports (2020). Geneva: WHO; (Accessed 5 Apr 2020)."}, {"Citation": "Aditya NP, Vathsala PG, Vieira V, Murthy RS, Souto EB. Advances in nanomedicines for malaria treatment. Adv Colloid Interface Sci (2013) 201-202:1\u201317. doi:\u00a010.1016/j.cis.2013.10.014", "ArticleIdList": ["10.1016/j.cis.2013.10.014", "24192063"]}, {"Citation": "Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. . Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure sars-Cov-2 prophylaxis among health care workers: A randomized clinical trial. JAMA Internal Med (2020). doi: 10.1001/jamainternmed.2020.6319", "ArticleIdList": ["10.1001/jamainternmed.2020.6319", "PMC7527945", "33001138"]}, {"Citation": "Axfors C, Schmitt AM, Janiaud P, van\u2019t Hooft J, Abd-Elsalam S, Abdo EF, et al. . Mortality outcomes with hydroxychloroquine and chloroquine in covid-19: An international collaborative meta-analysis of randomized trials. Nat Commun (2021) 12(1):2349. doi: 10.1038/s41467-021-22446-z", "ArticleIdList": ["10.1038/s41467-021-22446-z", "PMC8050319", "33859192"]}, {"Citation": "Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. . Lopinavir\u2013ritonavir in patients admitted to hospital with covid-19 (Recovery): A randomised, controlled, open-label, platform trial. Lancet (2020) 396(10259):1345\u201352. doi: 10.1016/S0140-6736(20)32013-4", "ArticleIdList": ["10.1016/S0140-6736(20)32013-4", "PMC7535623", "33031764"]}, {"Citation": "Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19. New Engl J Med (2020) 382(19):1787\u201399. doi: 10.1056/NEJMoa2001282", "ArticleIdList": ["10.1056/NEJMoa2001282", "PMC7121492", "32187464"]}, {"Citation": "Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. . Tocilizumab combined with favipiravir in the treatment of covid-19: A multicenter trial in a small sample size. Biomed Pharmacother (2020) 133:110825. doi: 10.1016/j.biopha.2020.110825", "ArticleIdList": ["10.1016/j.biopha.2020.110825", "PMC7524677", "33378989"]}, {"Citation": "Dro\u017cd\u017cal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. . Fda approved drugs with pharmacotherapeutic potential for sars-Cov-2 (Covid-19) therapy. Drug Resist Updates (2020) 100719.", "ArticleIdList": ["PMC7362818", "32717568"]}, {"Citation": "Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (Covid-19): A systematic review and meta-analysis. J Med Virol (2020). doi: 10.1002/jmv.26256", "ArticleIdList": ["10.1002/jmv.26256", "PMC7361300", "32617989"]}, {"Citation": "Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. Clin Microbiol Infect (2020).", "ArticleIdList": ["PMC7182750", "32344167"]}, {"Citation": "Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. . Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: An open-label, randomised, phase 2 trial. Lancet (2020) 395(10238):1695\u2013704. doi: 10.1016/S0140-6736(20)31042-4", "ArticleIdList": ["10.1016/S0140-6736(20)31042-4", "PMC7211500", "32401715"]}, {"Citation": "Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. . Ribavirin therapy for severe covid-19: A retrospective cohort study. Int J Antimicrob Agents (2020) 56(3):106114.", "ArticleIdList": ["PMC7377772", "32712334"]}, {"Citation": "Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning covid-19. J Med Virol (2020).", "ArticleIdList": ["PMC7228408", "32227493"]}, {"Citation": "Corum J, Wu KJ, Zimmer C. Coronavirus drug and treatment tracker. New York Times (2020)."}, {"Citation": "Chang Y-W, Yeh T-K, Lin K-T, Chen W-C, Yao H-T. Pharmacokinetics of anti-Sars-Cov agent niclosamide and its analogs in rats. J Food Drug Anal (2006) 14(4). doi: 10.38212/2224-6614.2464", "ArticleIdList": ["10.38212/2224-6614.2464"]}, {"Citation": "Wu C-J, Jan J-T, Chen C-M, Hsieh H-P, Hwang D-R, Liu H-W, et al. . Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrobial Agents Chemother (2004) 48(7):2693\u20136. doi: 10.1128/AAC.48.7.2693-2696.2004", "ArticleIdList": ["10.1128/AAC.48.7.2693-2696.2004", "PMC434198", "15215127"]}, {"Citation": "Pindiprolu SKS, Pindiprolu SH. Plausible mechanisms of niclosamide as an antiviral agent against covid-19. Med Hypotheses (2020) 109765. doi: 10.1016/j.mehy.2020.109765", "ArticleIdList": ["10.1016/j.mehy.2020.109765", "PMC7195103", "32361588"]}, {"Citation": "Chiba S. Effect of early oseltamivir on covid-19-Suspected outpatients without hypoxia. (2020).", "ArticleIdList": ["PMC7724617", "33296027"]}, {"Citation": "Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. . Dexamethasone in hospitalized patients with covid-19-Preliminary report. New Engl J Med (2020). doi: 10.1101/2020.06.22.20137273", "ArticleIdList": ["10.1101/2020.06.22.20137273", "PMC7383595", "32678530"]}, {"Citation": "Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. . Effect of hydrocortisone on mortality and organ support in patients with severe covid-19: The remap-cap covid-19 corticosteroid domain randomized clinical trial. Jama (2020) 324(13):1317\u201329.", "ArticleIdList": ["PMC7489418", "32876697"]}, {"Citation": "Dequin P-F, Heming N, Meziani F, Plantef\u00e8ve G, Voiriot G, Badi\u00e9 J, et al. . Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with covid-19: A randomized clinical trial. Jama (2020) 324(13):1298\u2013306. doi: 10.1001/jama.2020.16761", "ArticleIdList": ["10.1001/jama.2020.16761", "PMC7489432", "32876689"]}, {"Citation": "Furtado RH, Berwanger O, Fonseca HA, Corr\u00eaa TD, Ferraz LR, Lapa MG, et al. . Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe covid-19 in Brazil (Coalition ii): A randomised clinical trial. Lancet (2020) 396(10256):959\u201367. doi: 10.1016/S0140-6736(20)31862-6", "ArticleIdList": ["10.1016/S0140-6736(20)31862-6", "PMC7836431", "32896292"]}, {"Citation": "Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with covid-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Med (2020). doi: 10.1001/jamainternmed.2021.2209", "ArticleIdList": ["10.1001/jamainternmed.2021.2209", "PMC7577198", "33080017"]}, {"Citation": "Alvi MM, Sivasankaran S, Singh M. Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for covid-19. J Drug Target (2020) 28(7-8):742\u201354. doi: 10.1080/1061186X.2020.1793990", "ArticleIdList": ["10.1080/1061186X.2020.1793990", "32643436"]}, {"Citation": "Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. Covid-19: Consider Il6 receptor antagonist for the therapy of cytokine storm syndrome in sars-Cov-2 infected patients. J Med Virol (2020). doi: 10.1002/jmv.26078", "ArticleIdList": ["10.1002/jmv.26078", "PMC7283789", "32462717"]}, {"Citation": "Caracciolo M, Macheda S, Labate D, Tescione M, La Scala S, Vadal\u00e0 E, et al. . Case report: Canakinumab for the treatment of a patient with covid-19 acute respiratory distress syndrome. Front Immunol (2020) 11:1942. doi: 10.3389/fimmu.2020.01942", "ArticleIdList": ["10.3389/fimmu.2020.01942", "PMC7477112", "32983123"]}, {"Citation": "Sheng CC, Sahoo D, Dugar S, Prada RA, Wang TKM, Abou Hassan OK, et al. . Canakinumab to reduce deterioration of cardiac and respiratory function in sars-Cov-2 associated myocardial injury with heightened inflammation (Canakinumab in covid-19 cardiac injury: The three c study). Clin Cardiol (2020) 43(10):1055\u201363. doi: 10.1002/clc.23451", "ArticleIdList": ["10.1002/clc.23451", "PMC7461303", "32830894"]}, {"Citation": "Navarro-Mill\u00e1n I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of anakinra to prevent mechanical ventilation in severe covid-19: A case series. Arthritis Rheumatol (2020). doi: 10.1002/art.41422", "ArticleIdList": ["10.1002/art.41422", "PMC7361793", "32602262"]}, {"Citation": "Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. . Interleukin-1 blockade with high-dose anakinra in patients with covid-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol (2020). doi: 10.1016/S2665-9913(20)30127-2", "ArticleIdList": ["10.1016/S2665-9913(20)30127-2", "PMC7252085", "32501454"]}, {"Citation": "Cantini F, Niccoli L, Nannini C, Matarrese D, Di Natale ME, Lotti P, et al. . Beneficial impact of baricitinib in covid-19 moderate pneumonia; multicentre study. J Infect (2020) 81(4):647\u201379. doi: 10.1016/j.jinf.2020.06.052", "ArticleIdList": ["10.1016/j.jinf.2020.06.052", "PMC7313480", "32592703"]}, {"Citation": "Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for covid-19: A suitable treatment? Lancet Infect Dis (2020).", "ArticleIdList": ["PMC7270794", "32251638"]}, {"Citation": "Yeleswaram S, Smith P, Burn T, Covington M, Juvekar A, Li Y, et al. . Inhibition of cytokine signaling by ruxolitinib and implications for covid-19 treatment. Clin Immunol (2020), 108517.", "ArticleIdList": ["PMC7308779", "32585295"]}, {"Citation": "Bagca BG, Avci CB. The potential of Jak/Stat pathway inhibition by ruxolitinib in the treatment of covid-19. Cytokine Growth Factor Rev (2020) 54:51.", "ArticleIdList": ["PMC7305753", "32636055"]}, {"Citation": "Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. . Ruxolitinib in treatment of severe coronavirus disease 2019 (Covid-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol (2020).", "ArticleIdList": ["PMC7250105", "32470486"]}, {"Citation": "Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. . Inhibition of bruton tyrosine kinase in patients with severe covid-19. Sci Immunol 2020):5(48).", "ArticleIdList": ["PMC7274761", "32503877"]}, {"Citation": "Jodele S, K\u00f6hl J. Tackling covid-19 infection through complement-targeted immunotherapy. Br J Pharmacol (2020). doi:\u00a010.1111/bph.15187", "ArticleIdList": ["10.1111/bph.15187", "PMC7361469", "32643798"]}, {"Citation": "Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S. A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of intravenously administered ravulizumab compared with best supportive care in patients with covid-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome: A structured summary of a study protocol for a randomised controlled trial. Trials (2020) 21(1):639. doi:\u00a010.1186/s13063-020-04548-z", "ArticleIdList": ["10.1186/s13063-020-04548-z", "PMC7355517", "32660611"]}, {"Citation": "Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S. Infliximab for severe ulcerative colitis and subsequent sars-Cov-2 pneumonia: A stone for two birds. Gut (2020). doi: 10.1136/gutjnl-2020-321760", "ArticleIdList": ["10.1136/gutjnl-2020-321760", "32554621"]}, {"Citation": "Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, et al. . Covid-19 infection in crohn\u2019s disease under treatment with adalimumab. Gut (2020) 69(7):1364\u20135. doi: 10.1136/gutjnl-2020-321240", "ArticleIdList": ["10.1136/gutjnl-2020-321240", "32312788"]}, {"Citation": "Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in covid-19. Drugs (2020) 80(13):1267\u201392. doi: 10.1007/s40265-020-01367-z", "ArticleIdList": ["10.1007/s40265-020-01367-z", "PMC7372203", "32696108"]}, {"Citation": "J G\u00f3mez-Rial M-T. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in sars-Cov2 infection. In: Clinical immunology. Orlando, Fla; (2020).", "ArticleIdList": ["PMC7194539", "32335290"]}, {"Citation": "Bonaventura A, Vecchi\u00e9 A, Wang TS, Lee E, Cremer PC, Carey B, et al. . Targeting gm-csf in covid-19 pneumonia: Rationale and strategies. Front Immunol (2020) 11:1625. doi: 10.3389/fimmu.2020.01625", "ArticleIdList": ["10.3389/fimmu.2020.01625", "PMC7348297", "32719685"]}, {"Citation": "Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB, et al. . Therapeutic blockade of granulocyte macrophage colony-stimulating factor in covid-19-Associated hyperinflammation: Challenges and opportunities. Lancet Respir Med (2020) 8(8):822\u201330. doi:\u00a010.1016/s2213-2600(20)30267-8", "ArticleIdList": ["10.1016/s2213-2600(20)30267-8", "PMC7834476", "32559419"]}, {"Citation": "Melody M, Nelson J, Hastings J, Propst J, Smerina M, Mendez J, et al. . Case report: Use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy (2020) 12(15):1121\u20136. doi:\u00a010.2217/imt-2020-0136", "ArticleIdList": ["10.2217/imt-2020-0136", "PMC7319491", "32546029"]}, {"Citation": "Yang B, Fulcher JA, Ahn J, Berro M, Goodman-Meza D, Dhody K, et al. . Clinical characteristics and outcomes of covid-19 patients receiving compassionate use leronlimab. Clin Infect Dis An Off Publ Infect Dis Soc America (2020). doi:\u00a010.1093/cid/ciaa1583", "ArticleIdList": ["10.1093/cid/ciaa1583", "PMC7665416", "33079180"]}, {"Citation": "Mahase E. Covid-19: Fda authorises neutralising antibody bamlanivimab for non-admitted patients. BMJ (2020) 371:m4362. doi:\u00a010.1136/bmj.m4362", "ArticleIdList": ["10.1136/bmj.m4362", "33177042"]}, {"Citation": "Mahase E. Covid-19: Experts advise cautious optimism for neutralising antibodies after early results. BMJ (2020) 371:m3937. doi:\u00a010.1136/bmj.m3937", "ArticleIdList": ["10.1136/bmj.m3937", "33037029"]}, {"Citation": "Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. . Sars-Cov-2 neutralizing antibody ly-Cov555 in outpatients with covid-19. N Engl J Med (2020). doi:\u00a010.1056/NEJMoa2029849", "ArticleIdList": ["10.1056/NEJMoa2029849", "PMC7646625", "33113295"]}, {"Citation": "Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (Crs) of severe covid-19 and interleukin-6 receptor (Il-6r) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents (2020) 105954.", "ArticleIdList": ["PMC7118634", "32234467"]}, {"Citation": "Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. . Clinical characteristics of refractory covid-19 pneumonia in wuhan, China. Clin Infect Dis (2020) 73(11):e4208\u2013e4213. doi: 10.1093/cid/ciaa270", "ArticleIdList": ["10.1093/cid/ciaa270", "PMC7184444", "32173725"]}, {"Citation": "Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The covid-19 cytokine storm; what we know so far. Front Immunol (2020) 11:1446. doi: 10.3389/fimmu.2020.01446", "ArticleIdList": ["10.3389/fimmu.2020.01446", "PMC7308649", "32612617"]}, {"Citation": "Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. . Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med (2020) 382(18):1708\u201320.", "ArticleIdList": ["PMC7092819", "32109013"]}, {"Citation": "Siddiqi HK, Mehra MR. Covid-19 illness in native and immunosuppressed states: A clinical\u2013therapeutic staging proposal. J Heart Lung Transplant (2020) 39(5):405.", "ArticleIdList": ["PMC7118652", "32362390"]}, {"Citation": "Ali A, Kamjani MH, Kesselman MM. The role of tocilizumab in cytokine storm and improving outcomes in covid-19. Recent Pat Antiinfect Drug Discov (2020).", "ArticleIdList": ["32962623"]}, {"Citation": "Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. . Clinical characteristics of covid-19 in new York city. New Engl J Med (2020).", "ArticleIdList": ["PMC7182018", "32302078"]}, {"Citation": "Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee S-S, Chakraborty C. Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in covid-19. Arch Med Res (2020).", "ArticleIdList": ["PMC7241374", "32482373"]}, {"Citation": "Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. . Covid-19: Consider cytokine storm syndromes and immunosuppression. Lancet (London England) (2020) 395(10229):1033. doi: 10.1016/S0140-6736(20)30628-0", "ArticleIdList": ["10.1016/S0140-6736(20)30628-0", "PMC7270045", "32192578"]}, {"Citation": "Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, et al. . Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm. Chest (2020). doi: 10.2139/ssrn.3627337", "ArticleIdList": ["10.2139/ssrn.3627337", "PMC7567703", "33075378"]}, {"Citation": "Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease covid-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens (2020) 9(5):331. doi:\u00a010.3390/pathogens9050331", "ArticleIdList": ["10.3390/pathogens9050331", "PMC7280997", "32365466"]}, {"Citation": "Ul Qamar TM, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal (2020) 10(4):313\u20139. doi: 10.1016/j.jpha.2020.03.009", "ArticleIdList": ["10.1016/j.jpha.2020.03.009", "PMC7156227", "32296570"]}, {"Citation": "Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of covid-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints (2020) 20944:1\u201314. doi: 10.20944/preprints202003.0226.v1", "ArticleIdList": ["10.20944/preprints202003.0226.v1"]}, {"Citation": "Shaghaghi N. Molecular docking study of novel covid-19 protease with low risk terpenoides compounds of plants. ChemRxiv (2020) 10:1\u20139. doi: 10.26434/chemrxiv.11935722.v1", "ArticleIdList": ["10.26434/chemrxiv.11935722.v1"]}, {"Citation": "Nichols JM, Kaplan BL. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res (2020) 5(1):12\u201331. doi: 10.1089/can.2018.0073", "ArticleIdList": ["10.1089/can.2018.0073", "PMC7173676", "32322673"]}, {"Citation": "Brown JD. Cannabidiol as prophylaxis for sars-Cov-2 and covid-19? unfounded claims versus potential risks of medications during the pandemic. Res Soc Administrative Pharmacy: RSAP (2021) 17(1):2053. doi: 10.1016/j.sapharm.2020.03.020", "ArticleIdList": ["10.1016/j.sapharm.2020.03.020", "PMC7269703", "32273254"]}, {"Citation": "Nelson KM, Bisson J, Singh G, Graham JG, Chen S-N, Friesen JB, et al. . The essential medicinal chemistry of cannabidiol (Cbd). J Med Chem (2020) 63(21):12137\u201355. doi: 10.1021/acs.jmedchem.0c00724", "ArticleIdList": ["10.1021/acs.jmedchem.0c00724", "PMC7666069", "32804502"]}, {"Citation": "Costiniuk CT, Jenabian M-A. Acute inflammation and pathogenesis of sars-Cov-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Cytokine Growth Factor Rev (2020) 53:63\u201365. doi: 10.1016/j.cytogfr.2020.05.008", "ArticleIdList": ["10.1016/j.cytogfr.2020.05.008", "PMC7239000", "32467020"]}, {"Citation": "Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. . Immunomodulation in covid-19. Lancet Respir Med (2020) 8(6):544\u20136. doi: 10.1016/S2213-2600(20)30226-5", "ArticleIdList": ["10.1016/S2213-2600(20)30226-5", "PMC7198187", "32380023"]}, {"Citation": "\nCennimo D. Coronavirus disease 2019 (Covid-19) treatment & management: Approach considerations, medical care, prevention. Medscape Online (2020). Available at: https://emedicine.medscape.com/article/2500114-treatment?reg=1."}, {"Citation": "Rosas IO, Br\u00e4u N, Waters M, Go RC, Malhotra A, Hunter BD, et al. . Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine (2022) 47:101409. doi: 10.1016/j.eclinm.2022.101409", "ArticleIdList": ["10.1016/j.eclinm.2022.101409", "PMC9022847", "35475258"]}, {"Citation": "Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. . Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med (2021) 384(1):20\u201330. doi: 10.1056/NEJMoa2030340", "ArticleIdList": ["10.1056/NEJMoa2030340", "PMC7781101", "33332779"]}, {"Citation": "Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et al. . Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: Survival and clinical outcomes. Chest (2020) 158(4):1397\u2013408. doi: 10.1016/j.chest.2020.06.006", "ArticleIdList": ["10.1016/j.chest.2020.06.006", "PMC7831876", "32553536"]}, {"Citation": "Sloand JN, Nguyen TT, Zinck SA, Cook EC, Zimudzi TJ, Showalter SA, et al. . Ultrasound-guided cytosolic protein delivery Via transient fluorous masks. ACS Nano (2020) 14(4):4061\u201373. doi: 10.1021/acsnano.9b08745", "ArticleIdList": ["10.1021/acsnano.9b08745", "32134630"]}, {"Citation": "Mayer K. Nonviral crispr delivery vehicles lay the smart siege: Lipid-and polymer-based nanoparticles trust in guile more than force, so they're less likely to arouse immune resistance or wreak collateral damage. Genet Eng Biotechnol News (2020) 40(S4):S15\u2013S9. doi: 10.1089/gen.40.S4.05", "ArticleIdList": ["10.1089/gen.40.S4.05"]}, {"Citation": "Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, et al. . Fast and efficient Crispr/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger rna nanoparticles. Adv Mater (2019) 31(33):1902575. doi: 10.1002/adma.201902575", "ArticleIdList": ["10.1002/adma.201902575", "PMC6732788", "31215123"]}, {"Citation": "Chen G, Abdeen AA, Wang Y, Shahi PK, Robertson S, Xie R, et al. . A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol (2019) 14(10):974\u201380. doi: 10.1038/s41565-019-0539-2", "ArticleIdList": ["10.1038/s41565-019-0539-2", "PMC6778035", "31501532"]}, {"Citation": "Zhang X, Zhao W, Nguyen GN, Zhang C, Zeng C, Yan J, et al. . Functionalized lipid-like nanoparticles for in vivo mrna delivery and base editing. Sci Adv (2020) 6(34):eabc2315. doi: 10.1126/sciadv.abc2315", "ArticleIdList": ["10.1126/sciadv.abc2315", "PMC7442477", "32937374"]}, {"Citation": "Souto EB, Souto SB, Zielinska A, Durazzo A, Lucarini M, Santini A, et al. . Perillaldehyde 1,2-epoxide loaded sln-tailored mab: Production, physicochemical characterization and in vitro cytotoxicity profile in mcf-7 cell lines. Pharmaceutics (2020) 12(2):161. doi: 10.3390/pharmaceutics12020161", "ArticleIdList": ["10.3390/pharmaceutics12020161", "PMC7076521", "32079103"]}, {"Citation": "Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, et al. . Sustained transgene expression despite T lymphocyte responses in a clinical trial of Raav1-aat gene therapy. Proc Natl Acad Sci (2009) 106(38):16363\u20138. doi: 10.1073/pnas.0904514106", "ArticleIdList": ["10.1073/pnas.0904514106", "PMC2752529", "19706466"]}, {"Citation": "Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): Where are we, and how did we get here? Annu Rev Virol (2019) 6:601\u201321. doi: 10.1146/annurev-virology-092818-015530", "ArticleIdList": ["10.1146/annurev-virology-092818-015530", "PMC7123914", "31283441"]}, {"Citation": "Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani A, Chhablani J. Emerging therapies in neovascular age-related macular degeneration in 2020. Asia-Pac J Ophthalmol (2020) 9(3):250\u20139. doi: 10.1097/APO.0000000000000291", "ArticleIdList": ["10.1097/APO.0000000000000291", "PMC7299216", "32511123"]}, {"Citation": "Li S, Datta S, Brabbit E, Love Z, Woytowicz V, Flattery K, et al. . Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Ther (2021) 28(5):223\u201341. doi: 10.1038/s41434-020-0134-z", "ArticleIdList": ["10.1038/s41434-020-0134-z", "PMC7483267", "32123325"]}, {"Citation": "Bonaventura J, Eldridge MA, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, et al. . High-potency ligands for dreadd imaging and activation in rodents and monkeys. Nat Commun (2019) 10(1):1\u201312. doi: 10.1038/s41467-019-12236-z", "ArticleIdList": ["10.1038/s41467-019-12236-z", "PMC6788984", "31604917"]}, {"Citation": "Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, et al. . Igg-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-aav neutralizing antibodies. Nat Med (2020) 26(7):1096\u2013101. doi: 10.1038/s41591-020-0911-7", "ArticleIdList": ["10.1038/s41591-020-0911-7", "32483358"]}, {"Citation": "Pedersen NC. An update on feline infectious peritonitis: Virology and immunopathogenesis. Vet J (2014) 201(2):123\u201332. doi: 10.1016/j.tvjl.2014.04.017", "ArticleIdList": ["10.1016/j.tvjl.2014.04.017", "PMC7110662", "24837550"]}, {"Citation": "Morris KV. The improbability of the rapid development of a vaccine for sars-Cov-2. Mol Ther (2020) 28(7):1548\u20139. doi: 10.1016/j.ymthe.2020.06.005", "ArticleIdList": ["10.1016/j.ymthe.2020.06.005", "PMC7291966", "32533920"]}, {"Citation": "Tang Q, Li B, Woodle M, Lu PY. Application of sirna against sars in the rhesus macaque model. Rnai (2008) 442:139\u201358. doi: 10.1007/978-1-59745-191-8_11", "ArticleIdList": ["10.1007/978-1-59745-191-8_11", "PMC7121115", "18369784"]}, {"Citation": "Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, et al. . Extracellular ngfr spacers allow efficient tracking and enrichment of fully functional car-T cells Co-expressing a suicide gene. Front Immunol (2018) 9:507. doi: 10.3389/fimmu.2018.00507", "ArticleIdList": ["10.3389/fimmu.2018.00507", "PMC5871667", "29619024"]}, {"Citation": "Wu C-J, Huang H-W, Liu C-Y, Hong C-F, Chan Y-L. Inhibition of sars-cov replication by sirna. Antiviral Res (2005) 65(1):45\u20138. doi: 10.1016/j.antiviral.2004.09.005", "ArticleIdList": ["10.1016/j.antiviral.2004.09.005", "PMC7114151", "15652970"]}, {"Citation": "Ahn D-G, Lee W, Choi J-K, Kim S-J, Plant EP, Almaz\u00e1n F, et al. . Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses sars coronavirus replication. Antiviral Res (2011) 91(1):1\u201310. doi: 10.1016/j.antiviral.2011.04.009", "ArticleIdList": ["10.1016/j.antiviral.2011.04.009", "PMC4728714", "21549154"]}, {"Citation": "Shi Y, Luo H, Jia J, Xiong J, Yang D, Huang B, et al. . Antisense downregulation of sars-cov gene expression in vero E6 cells. J Gene Med (2005) 7(1):97\u2013107. doi: 10.1002/jgm.640", "ArticleIdList": ["10.1002/jgm.640", "PMC7166999", "15543523"]}, {"Citation": "Peeples L. News feature: Avoiding pitfalls in the pursuit of a covid-19 vaccine. Proc Natl Acad Sci (2020) 117(15):8218\u201321. doi: 10.1073/pnas.2005456117", "ArticleIdList": ["10.1073/pnas.2005456117", "PMC7165470", "32229574"]}, {"Citation": "Donia A, Bokhari H. Rna interference as a promising treatment against sars-Cov-2. Int Microbiol (2021) 24(1):123\u20134. doi: 10.1007/s10123-020-00146-w", "ArticleIdList": ["10.1007/s10123-020-00146-w", "PMC7462657", "32875426"]}, {"Citation": "Conforti A, Marra E, Roscilli G, Palombo F, Ciliberto G, Aurisicchio L. Are genetic vaccines the right weapon against covid-19? Mol Ther (2020) 28(7):1555\u20136. doi: 10.1016/j.ymthe.2020.06.007", "ArticleIdList": ["10.1016/j.ymthe.2020.06.007", "PMC7283060", "32553431"]}, {"Citation": "Liu MA. A comparison of plasmid DNA and mrna as vaccine technologies. Vaccines (2019) 7(2):37. doi: 10.3390/vaccines7020037", "ArticleIdList": ["10.3390/vaccines7020037", "PMC6631684", "31022829"]}, {"Citation": "Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. New Engl J Med (2020) 382(21):1969\u201373. doi: 10.1056/NEJMp2005630", "ArticleIdList": ["10.1056/NEJMp2005630", "32227757"]}, {"Citation": "Piyush R, Rajarshi K, Chatterjee A, Khan R, Ray S. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon (2020) 6(9):e05007. doi: 10.1016/j.heliyon.2020.e05007", "ArticleIdList": ["10.1016/j.heliyon.2020.e05007", "PMC7501848", "32984620"]}, {"Citation": "Chen J, Tang Y, Liu Y, Dou Y. Nucleic acid-based therapeutics for pulmonary diseases. AAPS PharmSciTech (2018) 19(8):3670\u201380. doi: 10.1208/s12249-018-1183-0", "ArticleIdList": ["10.1208/s12249-018-1183-0", "PMC7101845", "30338490"]}, {"Citation": "Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. . Tocilizumab in patients with severe covid-19: A retrospective cohort study. Lancet Rheumatol (2020) 2(8):e474\u2013e84. doi: 10.1016/S2665-9913(20)30173-9", "ArticleIdList": ["10.1016/S2665-9913(20)30173-9", "PMC7314456", "32835257"]}, {"Citation": "\u0141odyga M, Eder P, Bartnik W, Gonciarz M, K\u0142opocka M, Linke K, et al. . New pharmaceuticals in inflammatory bowel disease. Przeglad Gastroenterol (2015) 10(2):57.", "ArticleIdList": ["PMC4631272", "26557934"]}, {"Citation": "Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manage (2008) 4(4):767.", "ArticleIdList": ["PMC2621374", "19209259"]}, {"Citation": "Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet (2012) 379(9822):1214\u201324.", "ArticleIdList": ["PMC3316968", "22421340"]}, {"Citation": "Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. . Cytokine storm in Covid-19\u2013immunopathological mechanisms, clinical considerations, and therapeutic approaches: The reprogram consortium position paper. Front Immunol (2020) 11:1648. doi: 10.3389/fimmu.2020.01648", "ArticleIdList": ["10.3389/fimmu.2020.01648", "PMC7365905", "32754159"]}, {"Citation": "Scott LJ. Tocilizumab: A review in rheumatoid arthritis. Drugs (2017) 77(17):1865\u201379. doi: 10.1007/s40265-017-0829-7", "ArticleIdList": ["10.1007/s40265-017-0829-7", "PMC5736769", "29094311"]}, {"Citation": "Schulert GS. Can tocilizumab calm the cytokine storm of covid-19? Lancet Rheumatol (2020) 2(8):e449\u2013e51. doi: 10.1016/S2665-9913(20)30210-1", "ArticleIdList": ["10.1016/S2665-9913(20)30210-1", "PMC7314441", "32835248"]}, {"Citation": "Langer-Gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG, Ramanathan A, et al. . Early identification of covid-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis (2020) 99:291\u20137. doi: 10.1016/j.ijid.2020.07.081", "ArticleIdList": ["10.1016/j.ijid.2020.07.081", "PMC7406519", "32768693"]}, {"Citation": "Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med (2008) 26(6):711\u20135. doi: 10.1016/j.ajem.2007.10.031", "ArticleIdList": ["10.1016/j.ajem.2007.10.031", "18606328"]}, {"Citation": "Hirano T, Murakami M. Covid-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity (2020). doi: 10.1016/j.immuni.2020.04.003", "ArticleIdList": ["10.1016/j.immuni.2020.04.003", "PMC7175868", "32325025"]}, {"Citation": "Afif W, Loftus EV, Jr., Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. . Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 105(5):1133. doi: 10.1038/ajg.2010.9", "ArticleIdList": ["10.1038/ajg.2010.9", "PMC6937708", "20145610"]}, {"Citation": "Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip J, Peyrin-Biroulet L, et al. . Combination of c-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohn's Colitis (2015) 9(7):525\u201331. doi: 10.1093/ecco-jcc/jjv061", "ArticleIdList": ["10.1093/ecco-jcc/jjv061", "25895875"]}, {"Citation": "J\u00fcrgens M, John JMM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. . Levels of c-reactive protein are associated with response to infliximab therapy in patients with crohn's disease. Clin Gastroenterol Hepatol (2011) 9(5):421\u20137.e1. doi: 10.1016/j.cgh.2011.02.008", "ArticleIdList": ["10.1016/j.cgh.2011.02.008", "21334460"]}, {"Citation": "Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, et al. . Single-cell analysis of two severe covid-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun (2020) 11(1):1\u201311. doi: 10.1038/s41467-020-17834-w", "ArticleIdList": ["10.1038/s41467-020-17834-w", "PMC7413381", "32764665"]}, {"Citation": "Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, et al. . Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe covid-19 patients. EBioMedicine (2020) 57:102833. doi: 10.1016/j.ebiom.2020.102833", "ArticleIdList": ["10.1016/j.ebiom.2020.102833", "PMC7305897", "32574956"]}, {"Citation": "Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol (2019) 15(8):813\u201322. doi: 10.1080/1744666X.2019.1629904", "ArticleIdList": ["10.1080/1744666X.2019.1629904", "PMC7936577", "31219357"]}, {"Citation": "Moore JB, June CH. Cytokine release syndrome in severe covid-19. Science (2020) 368(6490):473\u20134. doi: 10.1126/science.abb8925", "ArticleIdList": ["10.1126/science.abb8925", "32303591"]}, {"Citation": "Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. . Effective treatment of severe covid-19 patients with tocilizumab. Proc Natl Acad Sci (2020) 117(20):10970\u20135.", "ArticleIdList": ["PMC7245089", "32350134"]}, {"Citation": "Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in covid-19: The current evidence and treatment strategies. Front Immunol (2020) 11:1708.", "ArticleIdList": ["PMC7365923", "32754163"]}, {"Citation": "Khodadadi H, Salles \u00c9L, Jarrahi A, Chibane F, Costigliola V, Yu JC, et al. . Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic rna. Cannabis Cannabinoid Res (2020) 5(3):197\u2013201. doi: 10.1089/can.2020.0043", "ArticleIdList": ["10.1089/can.2020.0043", "PMC7480719", "32923657"]}, {"Citation": "Hill KP. Cannabinoids and the coronavirus. Cannabis Cannabinoid Res (2020). doi: 10.1089/can.2020.0035", "ArticleIdList": ["10.1089/can.2020.0035", "PMC7347052", "32656343"]}, {"Citation": "Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by sars-Cov-2. Clin Chim Acta (2020). doi: 10.1016/j.cca.2020.06.017", "ArticleIdList": ["10.1016/j.cca.2020.06.017", "PMC7283076", "32531256"]}, {"Citation": "Land MH, MacNair L, Thomas BF, Peters EN, Bonn-Miller MO. Letter to the Editor: Possible drug\u2013drug interactions between cannabinoids and candidate covid-19 drugs. Cannabis Cannabinoid Res (2020) 5(4):340\u20133. doi: 10.1089/can.2020.0054", "ArticleIdList": ["10.1089/can.2020.0054", "PMC7759270", "33381648"]}, {"Citation": "Lowe HI, Toyang NJ, McLaughlin W. Potential of cannabidiol for the treatment of viral hepatitis. Pharmacogn Res (2017) 9(1):116. doi: 10.4103/0974-8490.199780", "ArticleIdList": ["10.4103/0974-8490.199780", "PMC5330095", "28250664"]}, {"Citation": "Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma\u2013associated herpesvirus-infected endothelium. Genes Cancer (2012) 3(7-8):512\u201320. doi: 10.1177/1947601912466556", "ArticleIdList": ["10.1177/1947601912466556", "PMC3527984", "23264851"]}, {"Citation": "Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG, Hallak JE, et al. . Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. Eur J Pharmacol (2019) 843:251\u20139. doi: 10.1016/j.ejphar.2018.11.029", "ArticleIdList": ["10.1016/j.ejphar.2018.11.029", "30481497"]}, {"Citation": "Ribeiro A, Almeida V, Costola-de-Souza C, Ferraz-de-Paula V, Pinheiro M, Vitoretti L, et al. . Cannabidiol improves lung function and inflammation in mice submitted to lps-induced acute lung injury. Immunopharmacol Immunotoxicol (2015) 37(1):35\u201341. doi: 10.3109/08923973.2014.976794", "ArticleIdList": ["10.3109/08923973.2014.976794", "25356537"]}, {"Citation": "Turner AJ, Hiscox JA, Hooper NM. Ace2: From vasopeptidase to sars virus receptor. Trends Pharmacol Sci (2004) 25(6):291\u20134. doi: 10.1016/j.tips.2004.04.001", "ArticleIdList": ["10.1016/j.tips.2004.04.001", "PMC7119032", "15165741"]}, {"Citation": "Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell rna-seq data analysis on the receptor Ace2 expression reveals the potential risk of different human organs vulnerable to 2019-ncov infection. Front Med (2020), 1\u20138. doi: 10.1007/s11684-020-0754-0", "ArticleIdList": ["10.1007/s11684-020-0754-0", "PMC7088738", "32170560"]}, {"Citation": "Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. . High expression of Ace2 receptor of 2019-ncov on the epithelial cells of oral mucosa. Int J Oral Sci (2020) 12(1):1\u20135. doi: 10.1038/s41368-020-0074-x", "ArticleIdList": ["10.1038/s41368-020-0074-x", "PMC7039956", "32094336"]}, {"Citation": "Hern\u00e1ndez-Cervantes R, M\u00e9ndez-D\u00edaz M, Prosp\u00e9ro-Garc\u00eda \u00d3, Morales-Montor J. Immunoregulatory role of cannabinoids during infectious disease. Neuroimmunomodulation (2017) 24(4-5):183\u201399. doi: 10.1159/000481824", "ArticleIdList": ["10.1159/000481824", "29151103"]}, {"Citation": "Pertwee RG. Cannabinoids [Handbook of experimental pharmacology 168]. Berlin Heidelberg: Springer-Verlag: (2005)."}, {"Citation": "Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther (2017) 175:133\u201350. doi: 10.1016/j.pharmthera.2017.02.041", "ArticleIdList": ["10.1016/j.pharmthera.2017.02.041", "28232276"]}, {"Citation": "Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. In: Kinghorn A., Falk H., Gibbons S., Kobayashi J.(eds) Phytocannabinoids. Progress in the Chemistry of Organic Natural Products. Cham: Springer; (2017) 103:103\u201331. doi: 10.1007/978-3-319-45541-9_4", "ArticleIdList": ["10.1007/978-3-319-45541-9_4", "PMC5345356", "28120232"]}, {"Citation": "De Petrocellis L, Ligresti A, Moriello AS, Allar\u00e0 M, Bisogno T, Petrosino S, et al. . Effects of cannabinoids and cannabinoid-enriched cannabis extracts on trp channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 163(7):1479\u201394. doi: 10.1111/j.1476-5381.2010.01166.x", "ArticleIdList": ["10.1111/j.1476-5381.2010.01166.x", "PMC3165957", "21175579"]}, {"Citation": "Aizpurua-Olaizola O, Soydaner U, O\u00fczt\u00fcrk E, Schibano D, Simsir Y, Navarro P, et al. . Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J Nat Prod (2016) 79(2):324\u201331. doi: 10.1021/acs.jnatprod.5b00949", "ArticleIdList": ["10.1021/acs.jnatprod.5b00949", "26836472"]}, {"Citation": "Russo EB. Taming thc: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol (2011) 163(7):1344\u201364. doi: 10.1111/j.1476-5381.2011.01238.x", "ArticleIdList": ["10.1111/j.1476-5381.2011.01238.x", "PMC3165946", "21749363"]}, {"Citation": "Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al. . Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 318(3):1375\u201387. doi: 10.1124/jpet.106.105247", "ArticleIdList": ["10.1124/jpet.106.105247", "16728591"]}, {"Citation": "De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, et al. . Non-thc cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. Br J Pharmacol (2013) 168(1):79\u2013102. doi: 10.1111/j.1476-5381.2012.02027.x", "ArticleIdList": ["10.1111/j.1476-5381.2012.02027.x", "PMC3570006", "22594963"]}, {"Citation": "Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to covid-19 based on an analysis of data of 150 patients from wuhan, China. Intensive Care Med (2020) 46(5):846\u20138. doi: 10.1007/s00134-020-05991-x", "ArticleIdList": ["10.1007/s00134-020-05991-x", "PMC7080116", "32125452"]}, {"Citation": "Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. . Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior phase iii trial. Crit Care Med (2016) 44(2):275. doi: 10.1097/CCM.0000000000001402", "ArticleIdList": ["10.1097/CCM.0000000000001402", "PMC5378312", "26584195"]}, {"Citation": "Chang YH, Lee ST, Lin WW. Effects of cannabinoids on lps-stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids. J Cell Biochem (2001) 81(4):715\u201323. doi: 10.1002/jcb.1103", "ArticleIdList": ["10.1002/jcb.1103", "11329626"]}, {"Citation": "Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol (2006) 1(1):50. doi: 10.1007/s11481-005-9007-x", "ArticleIdList": ["10.1007/s11481-005-9007-x", "18040791"]}, {"Citation": "Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F. Cannabinoid receptor type 2: A possible target in sars-Cov-2 (Cov-19) infection? Int J Mol Sci (2020) 21(11):3809. doi: 10.3390/ijms21113809", "ArticleIdList": ["10.3390/ijms21113809", "PMC7312493", "32471272"]}, {"Citation": "Sardinha J, Kelly M, Zhou J, Lehmann C. Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm (2014) 2014:978678. doi: 10.1155/2014/978678", "ArticleIdList": ["10.1155/2014/978678", "PMC3997158", "24803745"]}, {"Citation": "Youssef DA, El-Fayoumi HM, Mahmoud MF. Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of Cb2 and ppar-\u0393 receptors. Chemico-Biol Interact (2019) 297:16\u201324. doi: 10.1016/j.cbi.2018.10.010", "ArticleIdList": ["10.1016/j.cbi.2018.10.010", "30343038"]}, {"Citation": "Gertsch J, Leonti M, Raduner S, Racz I, Chen J-Z, Xie X-Q, et al. . Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci (2008) 105(26):9099\u2013104. doi: 10.1073/pnas.0803601105", "ArticleIdList": ["10.1073/pnas.0803601105", "PMC2449371", "18574142"]}, {"Citation": "Petrosino S, Verde R, Vaia M, Allar\u00e0 M, Iuvone T, Di Marzo V. Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacol Exp Ther (2018) 365(3):652\u201363. doi: 10.1124/jpet.117.244368", "ArticleIdList": ["10.1124/jpet.117.244368", "29632236"]}, {"Citation": "Yang L, Li F-F, Han Y-C, Jia B, Ding Y. Cannabinoid receptor Cb2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in mg-63 cells. Mediators Inflamm (2015) 2015:362126. doi: 10.1155/2015/362126", "ArticleIdList": ["10.1155/2015/362126", "PMC4310496", "25653478"]}, {"Citation": "Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol (2017) 39(5):529\u201339. doi: 10.1007/s00281-017-0629-x", "ArticleIdList": ["10.1007/s00281-017-0629-x", "PMC7079893", "28466096"]}, {"Citation": "Snyder RJ, Lantis J, Kirsner RS, Shah V, Molyneaux M, Carter MJ. Macrophages: A review of their role in wound healing and their therapeutic use. Wound Repair Regen (2016) 24(4):613\u201329. doi: 10.1111/wrr.12444", "ArticleIdList": ["10.1111/wrr.12444", "27196106"]}, {"Citation": "Punzo F, Bellini G, Tortora C, Di Pinto D, Argenziano M, Pota E, et al. . Mifamurtide and Tam-like macrophages: Effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget (2020) 11(7):687. doi: 10.18632/oncotarget.27479", "ArticleIdList": ["10.18632/oncotarget.27479", "PMC7041936", "32133045"]}, {"Citation": "Du Y, Ren P, Wang Q, Jiang S-K, Zhang M, Li J-Y, et al. . Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages. J Inflamm (2018) 15(1):1\u201312. doi: 10.1186/s12950-018-0201-z", "ArticleIdList": ["10.1186/s12950-018-0201-z", "PMC6278147", "30534003"]}, {"Citation": "Braun M, Khan ZT, Khan MB, Kumar M, Ward A, Achyut BR, et al. . Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury Via alternative macrophage polarization. Brain Behav Immun (2018) 68:224\u201337. doi: 10.1016/j.bbi.2017.10.021", "ArticleIdList": ["10.1016/j.bbi.2017.10.021", "PMC5767553", "29079445"]}, {"Citation": "Starc N, Ingo D, Conforti A, Rossella V, Tomao L, Pitisci A, et al. . Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency. Sci Rep (2017) 7(1):1\u201313. doi: 10.1038/s41598-017-08550-5", "ArticleIdList": ["10.1038/s41598-017-08550-5", "PMC5557950", "28811575"]}, {"Citation": "Gao F, Chiu S, Motan D, Zhang Z, Chen L, Ji H, et al. . Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis (2016) 7(1):e2062\u2013e. doi: 10.1038/cddis.2015.327", "ArticleIdList": ["10.1038/cddis.2015.327", "PMC4816164", "26794657"]}, {"Citation": "Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. . Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza a (H7n9) infection, a hint for covid-19 treatment. Engineering (2020) 6(10):1153\u201361. doi: 10.1016/j.eng.2020.02.006", "ArticleIdList": ["10.1016/j.eng.2020.02.006", "PMC7102606", "32292627"]}, {"Citation": "Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. . Transplantation of Ace2 (-) mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Dis (2020) 11:216\u201328. doi: 10.14336/AD.2020.0228", "ArticleIdList": ["10.14336/AD.2020.0228", "PMC7069465", "32257537"]}, {"Citation": "Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (Covid-19)-Induced pneumonia. Aging Dis (2020) 11(2):462. doi: 10.14336/AD.2020.0301", "ArticleIdList": ["10.14336/AD.2020.0301", "PMC7069463", "32257554"]}, {"Citation": "Foronjy RF, Dabo AJ, Cummins N, Geraghty P. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol (2014) 15(1):41. doi: 10.1186/s12865-014-0041-4", "ArticleIdList": ["10.1186/s12865-014-0041-4", "PMC4189665", "25277705"]}, {"Citation": "Golchin A, Farahany TZ, Khojasteh A, Soleimanifar F, Ardeshirylajimi A. The clinical trials of mesenchymal stem cell therapy in skin diseases: An update and concise review. Curr Stem Cell Res Ther (2019) 14(1):22\u201333. doi: 10.2174/1574888X13666180913123424", "ArticleIdList": ["10.2174/1574888X13666180913123424", "30210006"]}, {"Citation": "Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther (2019) 10(1):1\u201310. doi: 10.1186/s13287-018-1105-9", "ArticleIdList": ["10.1186/s13287-018-1105-9", "PMC6318883", "30606242"]}, {"Citation": "Metcalfe SM. Mesenchymal stem cells and management of covid-19 pneumonia. Med Drug Discov (2020) 5:100019. doi: 10.1016/j.medidd.2020.100019", "ArticleIdList": ["10.1016/j.medidd.2020.100019", "PMC7147223", "32296777"]}, {"Citation": "Franks LN, Ford BM, Prather PL. Selective estrogen receptor modulators: Cannabinoid receptor inverse agonists with differential Cb1 and Cb2 selectivity. Front Pharmacol (2016) 7:503. doi: 10.3389/fphar.2016.00503", "ArticleIdList": ["10.3389/fphar.2016.00503", "PMC5177629", "28066250"]}, {"Citation": "Kumar P, Song Z-H. Identification of raloxifene as a novel Cb2 inverse agonist. Biochem Biophys Res Commun (2013) 435(1):76\u201381. doi: 10.1016/j.bbrc.2013.04.040", "ArticleIdList": ["10.1016/j.bbrc.2013.04.040", "PMC5084446", "23611779"]}, {"Citation": "Dobovi\u0161ek L, Hojnik M, Ferk P. Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and Estrogens/Androgens on the periphery and their involvement in the pathogenesis of common diseases. Int J Mol Med (2016) 38(6):1642\u201351. doi: 10.3892/ijmm.2016.2779", "ArticleIdList": ["10.3892/ijmm.2016.2779", "27779654"]}, {"Citation": "Peretz J, Pekosz A, Lane AP, Klein SL. Estrogenic compounds reduce influenza a virus replication in primary human nasal epithelial cells derived from female, but not Male, donors. Am J Physiology-Lung Cell Mol Physiol (2016) 310(5):L415\u2013L25. doi: 10.1152/ajplung.00398.2015", "ArticleIdList": ["10.1152/ajplung.00398.2015", "PMC4773846", "26684252"]}, {"Citation": "Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol (2017) 198(10):4046\u201353. doi: 10.4049/jimmunol.1601896", "ArticleIdList": ["10.4049/jimmunol.1601896", "PMC5450662", "28373583"]}, {"Citation": "Rockwell CE, Raman P, Kaplan BL, Kaminski NE. A cox-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of il-2 secretion in activated jurkat T cells. Biochem Pharmacol (2008) 76(3):353\u201361. doi: 10.1016/j.bcp.2008.05.005", "ArticleIdList": ["10.1016/j.bcp.2008.05.005", "18571623"]}, {"Citation": "Carayon P, Marchand J, Dussossoy D, Derocq J-M, Jbilo O, Bord A, et al. . Modulation and functional involvement of Cb2 peripheral cannabinoid receptors during b-cell differentiation. Blood J Am Soc Hematol (1998) 92(10):3605\u201315. doi: 10.1182/blood.V92.10.3605", "ArticleIdList": ["10.1182/blood.V92.10.3605", "9808554"]}, {"Citation": "El Biali M, Broers B, Besson M, Demeules J. Cannabinoids and covid-19. Med Cannabis Cannabinoids (2020) 3(2):111\u20135. doi: 10.1159/000510799", "ArticleIdList": ["10.1159/000510799", "PMC7490504", "34671712"]}, {"Citation": "Tahamtan A, Samieipoor Y, Nayeri FS, Rahbarimanesh AA, Izadi A, Rashidi-Nezhad A, et al. . Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence (2018) 9(1):217\u201330. doi: 10.1080/21505594.2017.1389369", "ArticleIdList": ["10.1080/21505594.2017.1389369", "PMC5955186", "28992427"]}, {"Citation": "Farha MA, El-Halfawy OM, Gale RT, MacNair CR, Carfrae LA, Zhang X, et al. . Uncovering the hidden antibiotic potential of cannabis. ACS Infect Dis (2020) 6(3):338\u201346. doi: 10.1021/acsinfecdis.9b00419", "ArticleIdList": ["10.1021/acsinfecdis.9b00419", "32017534"]}, {"Citation": "Hobbs JM, Vazquez AR, Remijan ND, Trotter RE, McMillan TV, Freedman KE, et al. . Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res (2020) 34(7):1696\u20131703. doi: 10.1002/ptr.6651", "ArticleIdList": ["10.1002/ptr.6651", "32147925"]}, {"Citation": "Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. . The potential of cannabidiol in the covid-19 pandemic: A hypothesis letter. Br J Pharmacol (2020) 177(21):4967\u201370. doi: 10.22541/au.158894349.98427987", "ArticleIdList": ["10.22541/au.158894349.98427987", "PMC7300643", "32519753"]}, {"Citation": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497\u2013506. doi: 10.1016/S0140-6736(20)30183-5", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. In search of preventative strategies: Novel anti-inflammatory high-cbd cannabis sativa extracts modulate Ace2 expression in covid-19 gateway tissues. Aging (Albany NY) (2020) 12(22):22425\u201344. doi: 10.20944/preprints202004.0315.v1", "ArticleIdList": ["10.20944/preprints202004.0315.v1", "PMC7746344", "33221759"]}, {"Citation": "Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res (2017) 2(1):139\u201354. doi: 10.1089/can.2016.0034", "ArticleIdList": ["10.1089/can.2016.0034", "PMC5569602", "28861514"]}, {"Citation": "Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, et al. . Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2a receptor. Eur J Pharmacol (2012) 678(1-3):78\u201385. doi: 10.1016/j.ejphar.2011.12.043", "ArticleIdList": ["10.1016/j.ejphar.2011.12.043", "22265864"]}, {"Citation": "Huang S, Goplen NP, Zhu B, Cheon IS, Son Y, Wang Z, et al. . Macrophage ppar-\u0393 suppresses long-term lung fibrotic sequelae following acute influenza infection. PloS One (2019) 14(10):e0223430. doi: 10.1371/journal.pone.0223430", "ArticleIdList": ["10.1371/journal.pone.0223430", "PMC6777801", "31584978"]}, {"Citation": "Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. Ppar-\u0393 activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol (2010) 23(4):343\u201352. doi: 10.1089/vim.2010.0016", "ArticleIdList": ["10.1089/vim.2010.0016", "20712478"]}, {"Citation": "Mecha M, Feli\u00fa A, I\u00f1igo P, Mestre L, Carrillo-Salinas F, Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2a receptors. Neurobiol Dis (2013) 59:141\u201350. doi: 10.1016/j.nbd.2013.06.016", "ArticleIdList": ["10.1016/j.nbd.2013.06.016", "23851307"]}, {"Citation": "Millar SA, Stone N, Bellman Z, Yates A, England T, O'Sullivan S. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol (2019) 85(9):1888\u2013900. doi: 10.1111/bcp.14038", "ArticleIdList": ["10.1111/bcp.14038", "PMC6710502", "31222854"]}, {"Citation": "Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: Kinetics and interactions. Am J Med (2019) 132(11):1266\u201370. doi: 10.1016/j.amjmed.2019.05.017", "ArticleIdList": ["10.1016/j.amjmed.2019.05.017", "31152723"]}, {"Citation": "Costiniuk CT, Saneei Z, Routy J-P, Margolese S, Mandarino E, Singer J, et al. . Oral cannabinoids in people living with hiv on effective antiretroviral therapy: Ctn Pt028\u2013study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open (2019) 9(1):e024793. doi: 10.1136/bmjopen-2018-024793", "ArticleIdList": ["10.1136/bmjopen-2018-024793", "PMC6340429", "30659041"]}, {"Citation": "Reznik SE, Gardner EL, Ashby CR, Jr. Cannabidiol: A potential treatment for post Ebola syndrome? Int J Infect Dis (2016) 52:74\u20136. doi: 10.1016/j.ijid.2016.09.020", "ArticleIdList": ["10.1016/j.ijid.2016.09.020", "27686726"]}, {"Citation": "Doktorovov\u00e1 S, Kova\u010devi\u0107 AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. Eur J Pharmaceut Biopharmaceut (2016) 108:235\u201352. doi: 10.1016/j.ejpb.2016.08.001", "ArticleIdList": ["10.1016/j.ejpb.2016.08.001", "27519829"]}, {"Citation": "Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers\u2013a systematic review of in vitro data. Eur J Pharmaceut Biopharmaceut (2014) 87(1):1\u201318. doi: 10.1016/j.ejpb.2014.02.005", "ArticleIdList": ["10.1016/j.ejpb.2014.02.005", "24530885"]}, {"Citation": "Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev (2007) 59(6):478\u201390. doi: 10.1016/j.addr.2007.04.007", "ArticleIdList": ["10.1016/j.addr.2007.04.007", "17543416"]}, {"Citation": "Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto E, Ferreira D. Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway. Int J Pharmaceut (2012) 430(1-2):216\u201327. doi: 10.1016/j.ijpharm.2012.03.032", "ArticleIdList": ["10.1016/j.ijpharm.2012.03.032", "22465548"]}, {"Citation": "Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery\u2013liposomes versus lipid nanoparticles. Int J nanomed (2007) 2(4):595.", "ArticleIdList": ["PMC2676808", "18203427"]}, {"Citation": "Martins S, Silva A, Ferreira D, Souto E. Improving oral absorption of samon calcitonin by trimyristin lipid nanoparticles. J Biomed Nanotechnol (2009) 5(1):76\u201383. doi: 10.1166/jbn.2009.443", "ArticleIdList": ["10.1166/jbn.2009.443", "20055109"]}, {"Citation": "Fangueiro J, Gonzalez-Mira E, Martins-Lopes P, Egea M, Garcia M, Souto S, et al. . A novel lipid nanocarrier for insulin delivery: Production, characterization and toxicity testing. Pharm Dev Technol (2013) 18(3):545\u20139. doi: 10.3109/10837450.2011.591804", "ArticleIdList": ["10.3109/10837450.2011.591804", "21711084"]}, {"Citation": "Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: Limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv (2013) 10(7):889\u2013905. doi: 10.1517/17425247.2013.784742", "ArticleIdList": ["10.1517/17425247.2013.784742", "23550609"]}, {"Citation": "Souto E, M\u00fcller R. Cosmetic features and applications of lipid nanoparticles (Sln\u00ae, nlc\u00ae). Int J Cosmetic Sci (2008) 30(3):157\u201365. doi: 10.1111/j.1468-2494.2008.00433.x", "ArticleIdList": ["10.1111/j.1468-2494.2008.00433.x", "18452432"]}, {"Citation": "Souto EB, M\u00fcller RH. Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes. In: Drug delivery. Springer; (2010). p. 115\u201341.", "ArticleIdList": ["20217528"]}, {"Citation": "Souto E, Wissing S, Barbosa C, M\u00fcller R. Development of a controlled release formulation based on sln and nlc for topical clotrimazole delivery. Int J Pharmaceut (2004) 278(1):71\u20137. doi: 10.1016/j.ijpharm.2004.02.032", "ArticleIdList": ["10.1016/j.ijpharm.2004.02.032", "15158950"]}, {"Citation": "Saupe A, Wissing SA, Lenk A, Schmidt C, M\u00fcller RH. Solid lipid nanoparticles (Sln) and nanostructured lipid carriers (Nlc)\u2013structural investigations on two different carrier systems. Bio-medical Mater Eng (2005) 15(5):393\u2013402.", "ArticleIdList": ["16179760"]}, {"Citation": "Teeranachaideekul V, M\u00fcller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (Nlc)\u2013effects of formulation parameters on physicochemical stability. Int J Pharmaceut (2007) 340(1):198\u2013206. doi: 10.1016/j.ijpharm.2007.03.022", "ArticleIdList": ["10.1016/j.ijpharm.2007.03.022", "17482778"]}, {"Citation": "Souto EB, Fangueiro JF, M\u00fcller RH. Solid lipid nanoparticles (Sln\u2122). In: Fundamentals of pharmaceutical nanoscience. Springer; (2013). p. 91\u2013116."}, {"Citation": "Souto E, Almeida A, M\u00fcller R. Lipid nanoparticles (Sln\u00ae, nlc\u00ae) for cutaneous drug delivery: Structure, protection and skin effects. J Biomed Nanotechnol (2007) 3(4):317\u201331. doi: 10.1166/jbn.2007.049", "ArticleIdList": ["10.1166/jbn.2007.049"]}, {"Citation": "Zieli\u0144ska A, Nowak I. Solid lipid nanoparticles and nanostructured lipid carriers as novel carriers for cosmetic ingredients. In: Nanobiomaterials in galenic formulations and cosmetics. Elsevier; (2016). p. 231\u201355."}, {"Citation": "Zieli\u0144ska A, Ferreira NR, Durazzo A, Lucarini M, Cicero N, Mamouni SE, et al. . Development and optimization of alpha-Pinene-Loaded solid lipid nanoparticles (Sln) using experimental factorial design and dispersion analysis. Molecules (2019) 24(15):2683.", "ArticleIdList": ["PMC6696006", "31344802"]}, {"Citation": "Souto EB, Doktorovova S, Zielinska A, Silva AM. Key production parameters for the development of solid lipid nanoparticles by high shear homogenization. Pharm Dev Technol (2019) 24(9):1181\u20135. doi: 10.1080/10837450.2019.1647235", "ArticleIdList": ["10.1080/10837450.2019.1647235", "31354002"]}, {"Citation": "Souto EB, Zielinska A, Souto SB, Durazzo A, Lucarini M, Santini A, et al. . (+)-limonene 1, 2-Epoxide-Loaded slns: Evaluation of drug release, antioxidant activity, and cytotoxicity in an hacat cell line. Int J Mol Sci (2020) 21(4):1449. doi: 10.3390/ijms21041449", "ArticleIdList": ["10.3390/ijms21041449", "PMC7073088", "32093358"]}, {"Citation": "Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharmaceut (2008) 347(1-2):136\u201343. doi: 10.1016/j.ijpharm.2007.06.035", "ArticleIdList": ["10.1016/j.ijpharm.2007.06.035", "17709216"]}, {"Citation": "Patil HG, Tiwari RV, Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm (2016) 42(6):906\u201315. doi: 10.3109/03639045.2015.1088864", "ArticleIdList": ["10.3109/03639045.2015.1088864", "26472165"]}, {"Citation": "Joshi M, Patravale V. Nanostructured lipid carrier (Nlc) based gel of celecoxib. Int J Pharmaceut (2008) 346(1):124\u201332. doi: 10.1016/j.ijpharm.2007.05.060", "ArticleIdList": ["10.1016/j.ijpharm.2007.05.060", "17651933"]}, {"Citation": "Souto EB, Doktorovova S, Campos JR, Martins-Lopes P, Silva AM. Surface-tailored anti-Her2/Neu-Solid lipid nanoparticles for site-specific targeting mcf-7 and bt-474 breast cancer cells. Eur J Pharm Sci (2019) 128:27\u201335. doi:\u00a010.1016/j.ejps.2018.11.022", "ArticleIdList": ["10.1016/j.ejps.2018.11.022", "30472221"]}, {"Citation": "Eder P, Zieli\u0144ska A, Karczewski J, Dobrowolska A, S\u0142omski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-Tnf-A therapy in inflammatory bowel disease? current knowledge, future directions. J Nanobiotechnol (2021) 19(1):346. doi:\u00a010.1186/s12951-021-01090-1", "ArticleIdList": ["10.1186/s12951-021-01090-1", "PMC8554748", "34715852"]}, {"Citation": "Maroni A, Moutaharrik S, Zema L, Gazzaniga A. Enteric coatings for colonic drug delivery: State of the art. Expert Opin Drug Deliv (2017) 14(9):1027\u20139. doi:\u00a010.1080/17425247.2017.1360864", "ArticleIdList": ["10.1080/17425247.2017.1360864", "28749188"]}, {"Citation": "Kulbacka J, Pucek A, Kotulska M, Dubi\u0144ska-Magiera M, Rossowska J, Rols M-P, et al. . Electroporation and lipid nanoparticles with cyanine ir-780 and flavonoids as efficient vectors to enhanced drug delivery in colon cancer. Bioelectrochemistry (2016) 110:19\u201331. doi:\u00a010.1016/j.bioelechem.2016.02.013", "ArticleIdList": ["10.1016/j.bioelechem.2016.02.013", "26946158"]}, {"Citation": "Geng T, Lu C. Microfluidic electroporation for cellular analysis and delivery. Lab Chip (2013) 13(19):3803\u201321. doi:\u00a010.1039/c3lc50566a", "ArticleIdList": ["10.1039/c3lc50566a", "PMC3787074", "23917998"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "1", "Day": "19"}, {"Year": "2023", "Month": "3", "Day": "6"}, {"Year": "2023", "Month": "4", "Day": "11", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "10", "Hour": "4", "Minute": "0"}, {"Year": "2023", "Month": "4", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "22"}], "PublicationStatus": "epublish", "ArticleIdList": ["37033914", "PMC10073701", "10.3389/fimmu.2023.1147991"]}}], "PubmedBookArticle": []}